Clinical trial

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

NCT04882033

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-05-07

PhasePHASE1

Study timeline

Study start (estimated)2021-05-07Date precision: day

Registry last updated2021-05-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer Limited Stageunresolved

Interventions

Concurrent chemoradiotherapy plus anlotinibDRUG

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04882033 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.